Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23225712 | 0.97 | POLB (0.33) | LMNAPOLBRXFP1 | |
| SCHEMBL23225607 | 0.83 | TSHR (0.32) | LMNAPOLB | |
| SCHEMBL27102076 | 0.80 | KDM4E (0.31) | — | |
| SCHEMBL23218002 | 0.79 | LMNA (0.31) | LMNAPOLB | |
| SCHEMBL23225648 | 0.78 | LMNA (0.32) | LMNAPOLB | |
| SCHEMBL23218000 | 0.78 | LMNA (0.30) | LMNAPOLB | |
| SCHEMBL27103572 | 0.77 | OPRM1 (0.32) | LMNA | |
| SCHEMBL27102078 | 0.76 | MPO (0.45) | LMNARXFP1 | |
| SCHEMBL27102043 | 0.72 | TSHR (0.33) | LMNAPOLB | |
| SCHEMBL23217954 | 0.72 | MEN1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | BIOHAVEN THERAPEUTICS LTD. | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067651-A1 | PRODRUGS OF MYELOPEROXIDASE INHIBITORS | MPO, CAT, SOD1 | LMNA 2736/4885POLB 284/4885RXFP1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.